Eisai: Lecanemab to be presented at Alzheimer's Association

 BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab, an anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer's disease, at the Alzheimer's Association International Conference (AAIC). The conference will be held in Amsterdam, the Netherlands and virtually from July 16 to 20, 2023.

Key Eisai lecanemab AAIC presentations

• Amyloid Reduction and Evidence of Downstream Biomarker Modification
  • Presentation of results of Aβ, tau, neurodegeneration, gliosis, and imaging biomarkers in the Phase III, Clarity AD study of lecanemab (#80907)
• Drug Development in the Era of Anti-Amyloid Therapies
  • Discussion of considerations in the development of new drugs for AD and rational drug combinations based on pathophysiology (#70444)
• Subcutaneous Lecanemab is Predicted to Achieve Comparable Efficacy and Improved Safety Compared to Lecanemab IV in Early Alzheimer's Disease
• Presentation and discussion of results from studies to date on a subcutaneous formulation of lecanemab under development to potentially improve convenience and safety profile for patients (#82852)

https://www.biospace.com/article/releases/latest-data-on-lecanemab-to-be-presented-at-alzheimer-s-association-international-conference-aaic-2023/